4.8 Review

Efficacy and Mechanisms of Aerobic Exercise on Cancer Initiation, Progression, and Metastasis: A Critical Systematic Review of In Vivo Preclinical Data

期刊

CANCER RESEARCH
卷 76, 期 14, 页码 4032-4050

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-16-0887

关键词

-

类别

资金

  1. NCI NIH HHS [R01 CA040355, P30 CA008748] Funding Source: Medline

向作者/读者索取更多资源

A major objective of the emerging field of exercise-oncology research is to determine the efficacy of, and biological mechanisms by which, aerobic exercise affects cancer incidence, progression, and/or metastasis. There is a strong inverse association between self-reported exercise and the primary incidence of several forms of cancer; similarly, emerging data suggest that exercise exposure after a cancer diagnosis may improve outcomes for early-stage breast, colorectal, or prostate cancer. Arguably, critical next steps in the development of exercise as a candidate treatment in cancer control require preclinical studies to validate the biological efficacy of exercise, identify the optimal dose, and pinpoint mechanisms of action. To evaluate the current evidence base, we conducted a critical systematic review of in vivo studies investigating the effects of exercise in cancer prevention and progression. Studies were evaluated on the basis of tumor outcomes (e.g., incidence, growth, latency, metastasis), dose-response, and mechanisms of action, when available. A total of 53 studies were identified and evaluated on tumor incidence (n = 24), tumor growth (n = 33), or metastasis (n = 10). We report that the current evidence base is plagued by considerable methodologic heterogeneity in all aspects of study design, endpoints, and efficacy. Such heterogeneity precludes meaningful comparisons and conclusions at present. To this end, we provide a framework of methodologic and data reporting standards to strengthen the field to guide the conduct of high-quality studies required to inform translational, mechanism-driven clinical trials. (C)2016 AACR.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Editorial Material Obstetrics & Gynecology

Inflammatory vulvar dermatoses following immune checkpoint inhibitor therapy

Tiffany Y. Sia, Allison Betof Warner, Sarah J. Noor, Emeline M. Aviki, Kara Long Roche

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2023)

Review Oncology

Tumor-Infiltrating Lymphocyte Therapy in Melanoma: Facts to the Future

Allison Betof Warner, Pippa G. Corrie, Omid Hamid

Summary: Adoptive cell therapy with tumor-infiltrating lymphocytes (TIL) has shown durable responses in patients with advanced melanoma, but it is not yet approved by any regulatory agency. TIL therapy involves harvesting patient-specific T cells from tumors, expanding them ex vivo, and re-infusing them back into the patient. Objective response rates of 30% to 50% have been observed in heavily pretreated patients, including those who have progressed after other treatments. Improvements in patient selection, TIL production, and efficacy are currently being explored.

CLINICAL CANCER RESEARCH (2023)

Article Oncology

Real-world outcomes of different lines and sequences of treatment in BRAF-positive advanced melanoma patients

Allison Betof Warner, Ahmad Tarhini, Barinder Kang, Antonio Nakasato, You-Li Ling, Rohan Shah, Jackson Tang, Jeetvan Patel

Summary: The study compares the efficacy of different treatment sequences and lines among advanced melanoma patients with BRAF V600 mutation using real-world data. The results show that there is no significant difference in progression-free survival and overall survival between immunotherapies and targeted therapies, regardless of treatment sequence. However, the efficacy of second-line therapy is worse than first-line therapy. The study provides real-world evidence beyond clinical trials.

MELANOMA RESEARCH (2023)

Article Oncology

Decision-Making and Health-Related Quality of Life in Patients with Melanoma Considering Adjuvant Immunotherapy

Thomas M. Atkinson, Jennifer L. Hay, Soo Young Kim, Elizabeth Schofield, Michael A. Postow, Parisa Momtaz, Allison Betof Warner, Alexander N. Shoushtari, Margaret K. Callahan, Jedd D. Wolchok, Yuelin Li, Paul B. Chapman

Summary: This pilot study examined the factors influencing patients' decision on undergoing adjuvant anti-PD1 immunotherapy and their satisfaction with the decision. The study found that when provided with comprehensive quantitative information about the risks and benefits, 59% of patients chose observation while 41% opted for adjuvant immunotherapy. Patients choosing adjuvant immunotherapy had higher social well-being, more positive attitudes towards the treatment, and perceived their physician's preference for adjuvant therapy. They had lower decisional regret and higher satisfaction, even with poorer treatment outcomes.

ONCOLOGIST (2023)

Article Biochemistry & Molecular Biology

T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants

Daniel Hirschhorn, Sadna Budhu, Lukas Kraehenbuehl, Mathieu Gigoux, David Schroder, Andrew Chow, Jacob M. Ricca, Billel Gasmi, Olivier De Henau, Levi Mark B. Mangarin, Yanyun Li, Linda Hamadene, Anne-Laure Flamar, Hyejin Choi, Czrina A. Cortez, Cailian Liu, Aliya Holland, Sara Schad, Isabell Schulze, Allison Betof Warner, Travis J. Hollmann, Arshi Arora, Katherine S. Panageas, Gabrielle A. Rizzuto, Rebekka Duhen, Andrew D. Weinberg, Christine N. Spencer, David Ng, Xue-Yan He, Jean Albrengues, David Redmond, Mikala Egeblad, Jedd D. Wolchok, Taha Merghoub

Summary: Cancer immunotherapies can be ineffective due to tumor evolution and antigen-loss-variant clones. However, a combination of melanoma-specific CD4+ T cell therapy with OX40 co-stimulation or CTLA-4 blockade can eradicate melanomas containing antigen escape variants. The study reveals the importance of early recognition of melanoma antigens by tumor-specific CD4+ T cells and the role of neutrophils and inducible nitric oxide synthase in tumor eradication.
Correction Multidisciplinary Sciences

Neoadjuvant relatlimab and nivolumab in resectable melanoma (vol 611, pg 155, 2022)

Rodabe N. Amaria, Michael Postow, Elizabeth M. Burton, Michael T. Tetzlaff, Merrick I. Ross, Carlos Torres-Cabala, Isabella C. Glitza, Fei Duan, Denai R. Milton, Klaus Busam, Lauren Simpson, Jennifer L. McQuade, Michael K. Wong, Jeffrey E. Gershenwald, Jeffrey E. Lee, Ryan P. Goepfert, Emily Z. Keung, Sarah B. Fisher, Allison Betof-Warner, Alexander N. Shoushtari, Margaret Callahan, Daniel Coit, Edmund K. Bartlett, Danielle Bello, Parisa Momtaz, Courtney Nicholas, Aidi Gu, Xuejun Zhang, Brinda Rao Korivi, Madhavi Patnana, Sapna P. Patel, Adi Diab, Anthony Lucci, Victor G. Prieto, Michael A. Davies, James P. Allison, Padmanee Sharma, Jennifer A. Wargo, Charlotte Ariyan, Hussein A. Tawbi

NATURE (2023)

Article Public, Environmental & Occupational Health

Real-world treatment patterns and outcomes for patients with advanced melanoma treated with immunotherapy or targeted therapy

Sejin Lee, Antonia V. Bennett, Xi Zhou, Allison Betof Warner, Justin G. Trogdon, Erin E. Kent, Jennifer L. Lund

Summary: This study examined treatment patterns, sequence and outcomes for older adults with advanced melanoma who received first line immunotherapy or targeted therapy. The use of immunotherapy has increased steadily, with PD-1 inhibitors becoming the dominant treatment option since 2015. First line immunotherapy showed longer overall survival and time to treatment failure compared to targeted therapy. The most common treatment switch pattern involved transitioning from a first line CTLA-4 inhibitor to a second line PD-1 inhibitor. These findings provide valuable insights into the treatment patterns of immunotherapies and targeted therapies in older adults with advanced melanoma.

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2023)

Article Oncology

Beyond the 5-year milestone: Long-term survivorship of melanoma patients treated off-trial with anti-PD-1

Kimberly Loo, Hannah L. L. Kalvin, Katherine S. Panageas, Margaret K. K. Callahan, Paul B. B. Chapman, Parisa Momtaz, Alexander N. N. Shoushtari, Jedd D. D. Wolchok, Michael A. A. Postow, Allison Betof Warner

Summary: This retrospective cohort study investigated the long-term outcomes of patients with advanced nonuveal melanoma treated with anti-PD-1 therapy off clinical trials. The study found that patients who survived at least 5 years following their first anti-PD-1 dose had excellent overall survival and melanoma-specific survival rates.

PIGMENT CELL & MELANOMA RESEARCH (2023)

Letter Oncology

Diversity, equity, and inclusion in the melanoma research community

Marie E. Portuallo, David Y. Lu, Gretchen M. Alicea, Joel Bolling, Rebecca Lee, Jennifer McQuade, Allison Betof Warner, Michael Davies, Ashani Weeraratna, Jessie Villanueva, Vito W. Rebecca

Summary: The inaugural Diversity and Inclusion in Science Session discussed the need for diversity, equity, and inclusion in the melanoma research community and identified issues of inequity, bias, and harassment based on gender, ethnicity, and geographic location. The session revealed significant reports of discrimination, sexual harassment, and limited opportunities, highlighting the importance of creating an academic workplace culture that promotes mutual respect, fair access, and equal opportunities for all scientists in the field.

PIGMENT CELL & MELANOMA RESEARCH (2023)

Editorial Material Oncology

CD4+ TIL to the Rescue of Anti-PD-1 Failure by Targeting MHC-II

Allison Betof Warner, Jason J. Luke

Summary: This article discusses the potential of tumor-infiltrating lymphocyte therapy to overcome immune checkpoint inhibitor resistance through CD4(+)-mediated and MHC-II-dependent killing. Validating these results from human tumors has the potential to improve the clinical application of adoptive cellular transfer in advanced cancers.

CLINICAL CANCER RESEARCH (2023)

Article Medicine, Research & Experimental

Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy)

Paolo A. Ascierto, Sanjiv S. Agarwala, Allison Betof Warner, Marc S. Ernstoff, Bernard A. Fox, Thomas F. Gajewski, Jerome Galon, Claus Garbe, Brian R. Gastman, Jeffrey E. Gershenwald, Pawel Kalinski, Michelle Krogsgaard, Rom S. Leidner, Roger S. Lo, Alexander M. Menzies, Olivier Michielin, Poulikos I. Poulikakos, Jeffrey S. Weber, Corrado Caraco, Iman Osman, Igor Puzanov, Magdalena Thurin

Summary: Outcomes for melanoma patients have improved with the development of immunotherapies targeting immune checkpoint receptors and molecularly targeted therapies. Combinations of these treatments have shown improved prognosis compared to monotherapy. The search for biomarkers to guide treatment decisions and optimize therapies is still ongoing.

JOURNAL OF TRANSLATIONAL MEDICINE (2023)

Article Oncology

Exercise as an Immune Boost: Mechanism-Driven Support for Lifestyle Interventions

Allison Betof Warner

Summary: A study found that aerobic exercise improves tumor vasculature, enhances T-cell and myeloid-cell infiltration of the tumor through an ERK5-dependent mechanism, thus boosting the efficacy of immunotherapy.

CANCER IMMUNOLOGY RESEARCH (2023)

Article Oncology

A Clinical Study to Assess Diffuse Reflectance Spectroscopy with an Auto-Calibrated, Pressure-Sensing Optical Probe in Head and Neck Cancer

Ashlyn G. Rickard, Husam Mikati, Antoine Mansourati, Daniel Stevenson, Marlee Krieger, Daniel Rocke, Ramon Esclamado, Mark W. Dewhirst, Nirmala Ramanujam, Walter T. Lee, Gregory M. Palmer

Summary: Diffuse reflectance spectroscopy (DRS) is a powerful tool for quantifying optical and physiological tissue properties. In this clinical study, a pressure-sensing and automatic self-calibration DRS was assessed and validated in patients with head and neck squamous cell carcinoma (HNSCC). The results showed that cancerous tissues have a significantly lower hemoglobin saturation compared to normal tissues, suggesting tumor hypoxia. The study also demonstrated the feasibility of conducting optical spectroscopy measurements on intact lesions prior to removal during HNSCC procedures.

CURRENT ONCOLOGY (2023)

Article Oncology

The features and management of acquired resistance to PD1-based therapy in metastatic melanoma

Adriana Hepner, Judith M. Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojanielloh, Camille Lea Gerardi, Yanina J. L. Jansenj, Prachi Bhave, Bart Neyns, Andrew Haydon, Olivier Michielin, Joanna Manganan Oliver Klein, Alexander N. Shoushtari, Allison Betof Warner, Paolo Antonio Ascierto, Jennifer Leigh McQuade, Matteo S. Carlino, Lisa Zimmer, Celeste Lebbe, Douglas B. Johnson, Shahneen Sandhu, Victoria Atkinson, Christian U. Blank, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies

Summary: Acquired resistance to PD-1 therapy in melanoma is mainly oligometastatic, and patients may have a favorable survival outcome following salvage treatment.

EUROPEAN JOURNAL OF CANCER (2024)

Article Clinical Neurology

Leptomeningeal Carcinomatosis from Solid Tumor Malignancies: Treatment Strategies and Biomarkers

Rachna Malani, Ankush Bhatia, Allison Betof Warner, Jonathan T. Yang

Summary: Leptomeningeal metastases/diseases (LMDs) are a late-stage complication of solid tumor or hematologic malignancies. It is a disseminated disease which significantly affects the neurological system. Our understanding of its pathophysiology is currently lacking, but treatment strategies are constantly improving.

SEMINARS IN NEUROLOGY (2023)

暂无数据